Ionis Pharmaceuticals (IONS) Depreciation & Amortization (CF) (2013 - 2026)

Ionis Pharmaceuticals' Depreciation & Amortization (CF) history runs 14 years deep, the most recent figure standing at $3.3 million for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) rose 48.16% year-over-year to $3.3 million; the TTM figure through Mar 2026 stood at $11.1 million (up 19.21% YoY), while the FY2025 annual figure was $10.0 million, up 4.1% from the prior year.
• Depreciation & Amortization (CF) was $3.3 million for Q1 2026 at Ionis Pharmaceuticals, up from $3.3 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $3.8 million in Q3 2022 to a low of $2.2 million in Q1 2025.
• Historically, Depreciation & Amortization (CF) has averaged $2.8 million across 5 years, with a median of $2.5 million in 2024.
• The sharpest annual moves came in 2023 and 2026: Depreciation & Amortization (CF) plunged 33.9% in 2023, then surged 48.16% in 2026.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $3.0 million in 2022, then declined by 15.96% to $2.5 million in 2023, then retreated by 11.95% to $2.2 million in 2024, then soared by 45.49% to $3.3 million in 2025, then gained by 1.29% to $3.3 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $3.3 million (Q1 2026), $3.3 million (Q4 2025), and $2.3 million (Q3 2025), per Business Quant data.